Notice of Q3 2017 Trading Update

13 July 2017

UDG Healthcare plc

Notice of Q3 2017 Trading Update

UDG Healthcare plc ("UDG Healthcare" or "Group"), a leading international healthcare services provider, will issue a trading update for the third quarter to 30 June 2017 at 7.00am (BST) on Thursday, 3 August 2017.

The Company will also host a conference call for investors and analysts at 8.30am (BST) on Thursday, 3 August 2017 to discuss the statement. The dial-in details are as follows:

A playback facility will be available for seven days on +44 (0) 20 8196 1998. The access code for the replay will be 4912553#.

For further information, please contact:

Keith Byrne

Head of Investor Relations, Strategy & Corporate Communications

UDG Healthcare plc

Tel: +353-1-468-9000

Lisa Kavanagh / Jack Hickey / Nick Brown

Powerscourt

Tel: +44-207-250-1446

Email: [email protected]

About UDG Healthcare plc:

UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering commercial, clinical, communications and packaging services to the healthcare industry, employing almost 8,000 people with operations in 23 countries and delivering services in over 50 countries.

UDG Healthcare plc operates across three divisions: Ashfield, Sharp and Aquilant.

Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across two broad areas of activity: commercial & clinical services, and communications services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.

Sharp is a global leader in contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, operating from state of the art facilities across the US and Europe. Sharp is also a world leader in 'Track and Trace' serialisation services, which will require all prescription drugs to have a unique serial code for authentication and traceability.

Aquilant is a leading provider of outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK, Ireland and the Netherlands.

The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.

For more information please go to: www.udghealthcare.com